NAFLD patients display increased serum levels of angiogenic markers such as VEGF, soluble VEGFR-1 (sVEGFR1) and sVEGFR2 [16]. The gene discussed is VEGFA; the disease is metabolic dysfunction-associated steatotic liver disease.